LILRB4/CD85k/ILT3 Antibodies

LILRB4, also known as ILT3, CD85k, and LIR-5, is a transmembrane glycoprotein that is expressed on dendritic cells (DC), monocytes, macrophages, and vascular endothelial cells (EC). Ligation of LILRB4 triggers ITIM-mediated inhibition of cell-activating signaling, leading to enhanced immune tolerance and reduced allogeneic graft rejection. Soluble LILRB4 induces the differentiation of CD8+ T suppressor cells (Ts) that can inhibit the effector functions of CD4+ Th cells and CD8+ CTL. In turn, CD8+ Ts cells induce LILRB4 upregulation and a tolerogenic phenotype in monocytes, DC, and EC.